Lilly strikes $5.9 billion oncology deal with Stipple Bio to develop next-gen cancer therapies
By: IPP Bureau
Last updated : November 19, 2026 10:21 am
Eli Lilly is teaming up with Cambridge-based biotech company Stipple Bio in a multi-target, multi-modality oncology research collaboration that could be worth up to $5.9 billion, as the pharmaceutical giant expands its efforts to develop next-generation cancer therapies.
Under the strategic research collaboration and license agreement announced on November 16, Stipple Bio will use its proprietary Pointillist Platform to identify novel tumor-specific cell surface epitope binders. Lilly will combine these discoveries with its own oncology technologies to develop potential cancer treatments across multiple modalities.
The collaboration aims to address one of the longstanding challenges in cancer treatment: selectively attacking tumor cells while sparing healthy tissue.
Stipple Bio’s Pointillist Platform is designed to identify specific molecular features, or epitopes, on the surface of cancer cells. By targeting these tumor-specific markers, the company aims to develop therapies with greater precision, potentially improving efficacy while reducing damage to healthy cells.
“Stipple Bio was founded with the belief that epitope-level precision could distinguish tumor cells from healthy tissue, unlocking a new generation of effective and safer cancer therapies directed at targets whose expression on healthy cells has historically limited their clinical utility,” said Jeff Landau, Chief Executive Officer of Stipple Bio.
“Lilly brings tremendous expertise in oncology drug discovery and development. We look forward to working with Lilly’s exceptional oncology team and technologies to bring a new generation of precision cancer therapies to patients.”
Landau added, “This collaboration represents an important step in realizing the broad therapeutic opportunities enabled by our platform, while allowing us to continue advancing our pipeline.”
Under the agreement, Stipple Bio will receive an upfront payment and an equity investment from Lilly.
Lilly, in turn, will secure exclusive worldwide rights to develop and commercialize products emerging from the collaboration.
Stipple Bio could receive aggregate payments of up to $5.9 billion upon the achievement of research, product development and commercialization milestones. The company will also be eligible for tiered royalties on product sales if Lilly successfully brings therapies from the collaboration to market.
The agreement gives Lilly access to Stipple Bio’s epitope-level targeting technology while allowing the biotech to continue developing its broader pipeline.
Founded to advance precision oncology, Stipple Bio is building a multi-modality pipeline of therapeutics powered by its Pointillist Platform.
The company plans to initiate a Phase 1 clinical trial for its lead asset, STP-100, a first-in-class antibody-drug conjugate (ADC), in early 2027. The programme will target solid tumors, including pancreatic cancer.
The Lilly collaboration marks a significant step in the company's strategy to translate its tumor-specific targeting technology into a broader range of cancer treatments.